

Raymond W Lam

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1025365/publications.pdf>

Version: 2024-02-01

395
papers

20,287
citations

11608

70
h-index

16127

124
g-index

413
all docs

413
docs citations

413
times ranked

15614
citing authors

#	ARTICLE	IF	CITATIONS
1	Canadian Network for Mood and Anxiety Treatments (<scp>CANMAT</scp>) and International Society for Bipolar Disorders (<scp>ISBD</scp>) 2018 guidelines for the management of patients with bipolar disorder. <i>Bipolar Disorders</i> , 2018, 20, 97-170.	1.1	1,079
2	Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 Clinical Guidelines for the Management of Adults with Major Depressive Disorder. <i>Canadian Journal of Psychiatry</i> , 2016, 61, 540-560.	0.9	746
3	Effectiveness of theta burst versus high-frequency repetitive transcranial magnetic stimulation in patients with depression (THREE-D): a randomised non-inferiority trial. <i>Lancet, The</i> , 2018, 391, 1683-1692.	6.3	706
4	Canadian clinical practice guidelines for the management of anxiety, posttraumatic stress and obsessive-compulsive disorders. <i>BMC Psychiatry</i> , 2014, 14, S1.	1.1	569
5	Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 Clinical Guidelines for the Management of Adults with Major Depressive Disorder. <i>Canadian Journal of Psychiatry</i> , 2016, 61, 561-575.	0.9	415
6	Subcallosal cingulate deep brain stimulation for treatment-resistant depression: a multisite, randomised, sham-controlled trial. <i>Lancet Psychiatry, the</i> , 2017, 4, 839-849.	3.7	382
7	Canadian Network for Mood and Anxiety Treatments (CANMAT) Clinical guidelines for the management of major depressive disorder in adults.. <i>Journal of Affective Disorders</i> , 2009, 117, S26-S43.	2.0	357
8	Brain-derived neurotrophic factor and inflammatory markers in patients with early- vs. late-stage bipolar disorder. <i>International Journal of Neuropsychopharmacology</i> , 2009, 12, 447.	1.0	343
9	Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 Clinical Guidelines for the Management of Adults with Major Depressive Disorder. <i>Canadian Journal of Psychiatry</i> , 2016, 61, 524-539.	0.9	340
10	The interpersonal expression of perfection: Perfectionistic self-presentation and psychological distress.. <i>Journal of Personality and Social Psychology</i> , 2003, 84, 1303-1325.	2.6	326
11	A multicenter pilot study of subcallosal cingulate area deep brain stimulation for treatment-resistant depression. <i>Journal of Neurosurgery</i> , 2012, 116, 315-322.	0.9	319
12	A systematic review and meta-analysis of randomized, double-blind, placebo-controlled trials of ketamine in the rapid treatment of major depressive episodes. <i>Psychological Medicine</i> , 2015, 45, 693-704.	2.7	311
13	Cognitive Dysfunction in Major Depressive Disorder: Effects on Psychosocial Functioning and Implications for Treatment. <i>Canadian Journal of Psychiatry</i> , 2014, 59, 649-654.	0.9	276
14	Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 Clinical Guidelines for the Management of Adults with Major Depressive Disorder. <i>Canadian Journal of Psychiatry</i> , 2016, 61, 576-587.	0.9	227
15	Chronotherapeutics (light and wake therapy) in affective disorders. <i>Psychological Medicine</i> , 2005, 35, 939-944.	2.7	216
16	Repetitive Transcranial Magnetic Stimulation for Treatment-Resistant Depression: A Systematic Review and Metaanalysis. <i>Canadian Journal of Psychiatry</i> , 2008, 53, 621-631.	0.9	211
17	Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 Clinical Guidelines for the Management of Adults with Major Depressive Disorder. <i>Canadian Journal of Psychiatry</i> , 2016, 61, 510-523.	0.9	209
18	The Can-SAD Study: A Randomized Controlled Trial of the Effectiveness of Light Therapy and Fluoxetine in Patients With Winter Seasonal Affective Disorder. <i>American Journal of Psychiatry</i> , 2006, 163, 805-812.	4.0	200

#	ARTICLE	IF	CITATIONS
19	Quality of life in bipolar disorder: a review of the literature. <i>Health and Quality of Life Outcomes</i> , 2005, 3, 72.	1.0	195
20	Canadian Network for Mood and Anxiety Treatments (CANMAT) Clinical guidelines for the management of major depressive disorder in adults. <i>Journal of Affective Disorders</i> , 2009, 117, S1-S2.	2.0	192
21	Efficacy of Bright Light Treatment, Fluoxetine, and the Combination in Patients With Nonseasonal Major Depressive Disorder. <i>JAMA Psychiatry</i> , 2016, 73, 56.	6.0	191
22	Bipolar Disorder and Quality of Life: A Patient-Centered Perspective. <i>Quality of Life Research</i> , 2006, 15, 25-37.	1.5	190
23	Brain glutamate levels measured by magnetic resonance spectroscopy in patients with bipolar disorder: a meta-analysis. <i>Bipolar Disorders</i> , 2012, 14, 478-487.	1.1	184
24	Canadian Network for Mood and Anxiety Treatments (CANMAT) Clinical guidelines for the management of major depressive disorder in adults.. <i>Journal of Affective Disorders</i> , 2009, 117, S44-S53.	2.0	175
25	Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 Clinical Guidelines for the Management of Adults with Major Depressive Disorder. <i>Canadian Journal of Psychiatry</i> , 2016, 61, 588-603.	0.9	165
26	Brain Serotonin ₂ Receptors in Major Depression. <i>Archives of General Psychiatry</i> , 2000, 57, 850.	13.8	159
27	The Relationship Between Neurocognitive and Psychosocial Functioning in Major Depressive Disorder. <i>Journal of Clinical Psychiatry</i> , 2014, 75, 1359-1370.	1.1	158
28	Canadian Network for Mood and Anxiety Treatments (CANMAT) Clinical guidelines for the management of major depressive disorder in adults. II. Psychotherapy alone or in combination with antidepressant medication. <i>Journal of Affective Disorders</i> , 2009, 117, S15-S25.	2.0	154
29	Effects of Rapid Tryptophan Depletion in Patients With Seasonal Affective Disorder in Remission After Light Therapy. <i>Archives of General Psychiatry</i> , 1996, 53, 41.	13.8	149
30	MicroRNAs 146a/b-5 and 425-3p and 24-3p are markers of antidepressant response and regulate MAPK/Wnt-system genes. <i>Nature Communications</i> , 2017, 8, 15497.	5.8	144
31	Decrease in Brain Serotonin 2 Receptor Binding in Patients With Major Depression Following Desipramine Treatment. <i>Archives of General Psychiatry</i> , 1999, 56, 705.	13.8	141
32	Which antidepressants have demonstrated superior efficacy? A review of the evidence. <i>International Clinical Psychopharmacology</i> , 2007, 22, 323-329.	0.9	137
33	Neurocognitive Functioning in Patients With Bipolar I Disorder Recently Recovered From a First Manic Episode. <i>Journal of Clinical Psychiatry</i> , 2010, 71, 1234-1242.	1.1	134
34	Canadian Network for Mood and Anxiety Treatments (CANMAT) Clinical Guidelines for the Management of Major Depressive Disorder in Adults. I. Classification, Burden and Principles of Management. <i>Journal of Affective Disorders</i> , 2009, 117, S5-S14.	2.0	128
35	Efficacy of escitalopram in the treatment of major depressive disorder compared with conventional selective serotonin reuptake inhibitors and venlafaxine XR: a meta-analysis. <i>Journal of Psychiatry and Neuroscience</i> , 2006, 31, 122-31.	1.4	128
36	PET Study of [18F]6-Fluoro-l-Dopa Uptake in Neuroleptic- and Mood-Stabilizer-Naive First-Episode Nonpsychotic Mania: Effects of Treatment With Divalproex Sodium. <i>American Journal of Psychiatry</i> , 2002, 159, 768-774.	4.0	123

#	ARTICLE	IF	CITATIONS
37	Cognitive Impairment in Patients With Depression: Awareness, Assessment, and Management. <i>Journal of Clinical Psychiatry</i> , 2017, 78, 1383-1394.	1.1	123
38	The effect of intravenous, intranasal, and oral ketamine in mood disorders: A meta-analysis. <i>Journal of Affective Disorders</i> , 2020, 276, 576-584.	2.0	118
39	Sleep disturbances and depression: a challenge for antidepressants. <i>International Clinical Psychopharmacology</i> , 2006, 21, S25-S29.	0.9	114
40	Discovering biomarkers for antidepressant response: protocol from the Canadian biomarker integration network in depression (CAN-BIND) and clinical characteristics of the first patient cohort. <i>BMC Psychiatry</i> , 2016, 16, 105.	1.1	114
41	The chronotherapeutic treatment of bipolar disorders: A systematic review and practice recommendations from the ISBD task force on chronotherapy and chronobiology. <i>Bipolar Disorders</i> , 2019, 21, 741-773.	1.1	113
42	Antidepressant-Associated Mood Elevations in Bipolar II Disorder Compared With Bipolar I Disorder and Major Depressive Disorder. <i>Journal of Clinical Psychiatry</i> , 2008, 69, 1589-1601.	1.1	113
43	The impact of bipolar disorder upon work functioning: a qualitative analysis. <i>Bipolar Disorders</i> , 2007, 9, 126-143.	1.1	109
44	Safety and efficacy of adjunctive second-generation antidepressant therapy with a mood stabiliser or an atypical antipsychotic in acute bipolar depression: a systematic review and meta-analysis of randomised placebo-controlled trials. <i>Lancet Psychiatry</i> , 2016, 3, 1138-1146.	3.7	109
45	Divalproex sodium versus placebo in the treatment of acute bipolar depression: A systematic review and meta-analysis. <i>Journal of Affective Disorders</i> , 2010, 124, 228-234.	2.0	106
46	Combining Antidepressants for Treatment-Resistant Depression. <i>Journal of Clinical Psychiatry</i> , 2002, 63, 685-693.	1.1	103
47	Enhancing outcomes in the management of treatment resistant depression: a focus on atypical antipsychotics. <i>Bipolar Disorders</i> , 2003, 5, 36-47.	1.1	100
48	Seasonal Affective Disorder: A Clinical Update. <i>Annals of Clinical Psychiatry</i> , 2007, 19, 239-246.	0.6	100
49	The THINC-Integrated Tool (THINC-it) Screening Assessment for Cognitive Dysfunction. <i>Journal of Clinical Psychiatry</i> , 2017, 78, 873-881.	1.1	100
50	The dopamine-4 receptor gene associated with binge eating and weight gain in women with seasonal affective disorder: An evolutionary perspective. <i>Biological Psychiatry</i> , 2004, 56, 665-669.	0.7	94
51	A systematic review and meta-analysis of randomized controlled trials of adjunctive ketamine in electroconvulsive therapy: Efficacy and tolerability. <i>Journal of Psychiatric Research</i> , 2015, 62, 23-30.	1.5	93
52	Trajectories of Response to Dorsolateral Prefrontal rTMS in Major Depression: A THREE-D Study. <i>American Journal of Psychiatry</i> , 2019, 176, 367-375.	4.0	93
53	Canadian Network for Mood and Anxiety Treatments (CANMAT) Clinical guidelines for the management of major depressive disorder in adults. <i>Journal of Affective Disorders</i> , 2009, 117, S54-S64.	2.0	91
54	A controlled study of light therapy in women with late luteal phase dysphoric disorder. <i>Psychiatry Research</i> , 1999, 86, 185-192.	1.7	90

#	ARTICLE	IF	CITATIONS
55	Childhood Inattention and Dysphoria and Adult Obesity Associated with the Dopamine D4 receptor Gene in Overeating Women with Seasonal Affective Disorder. <i>Neuropsychopharmacology</i> , 2004, 29, 179-186.	2.8	90
56	Melatonin suppression in bipolar and unipolar mood disorders. <i>Psychiatry Research</i> , 1990, 33, 129-134.	1.7	88
57	PET Study of the Effects of Valproate on Dopamine D2Receptors in Neuroleptic- and Mood-Stabilizer-Naive Patients With Nonpsychotic Mania. <i>American Journal of Psychiatry</i> , 2002, 159, 1718-1723.	4.0	86
58	Perceived Quality of Life in Patients with Bipolar Disorder. Does Group Psychoeducation Have an Impact?. <i>Canadian Journal of Psychiatry</i> , 2005, 50, 95-100.	0.9	85
59	Course and Outcome after the First Manic Episode in Patients with Bipolar Disorder: Prospective 12-Month Data from the Systematic Treatment Optimization Program for Early Mania Project. <i>Canadian Journal of Psychiatry</i> , 2009, 54, 105-112.	0.9	85
60	Seasonal depression. <i>Journal of Affective Disorders</i> , 2001, 63, 123-132.	2.0	82
61	Effects of rapid tryptophan depletion on brain 5-HT ₂ receptors: a PET study. <i>British Journal of Psychiatry</i> , 2001, 178, 448-453.	1.7	81
62	Polymorphism of the serotonin-2A receptor gene (HTR2A) associated with childhood attention deficit hyperactivity disorder (ADHD) in adult women with seasonal affective disorder. <i>Journal of Affective Disorders</i> , 2002, 71, 229-233.	2.0	81
63	Update on the Biology of Seasonal Affective Disorder. <i>CNS Spectrums</i> , 2005, 10, 635-646.	0.7	80
64	Evidence of a Biological Effect of Light Therapy on the Retina of Patients with Seasonal Affective Disorder. <i>Biological Psychiatry</i> , 2009, 66, 253-258.	0.7	79
65	A Birth-Season/DRD4 Gene Interaction Predicts Weight Gain and Obesity in Women with Seasonal Affective Disorder: A Seasonal Thrifty Phenotype Hypothesis. <i>Neuropsychopharmacology</i> , 2006, 31, 2498-2503.	2.8	77
66	Effect of electroconvulsive therapy on brain 5-HT ₂ receptors in major depression. <i>British Journal of Psychiatry</i> , 2010, 196, 474-479.	1.7	76
67	Clinical effectiveness: The importance of psychosocial functioning outcomes. <i>Journal of Affective Disorders</i> , 2011, 132, S9-S13.	2.0	76
68	Burden of Bipolar Depression. <i>CNS Drugs</i> , 2008, 22, 389-406.	2.7	75
69	Citalopram and Bupropion-SR. <i>Journal of Clinical Psychiatry</i> , 2004, 65, 337-340.	1.1	75
70	Machine learning and big data analytics in bipolar disorder: A position paper from the International Society for Bipolar Disorders Big Data Task Force. <i>Bipolar Disorders</i> , 2019, 21, 582-594.	1.1	74
71	The Canadian Network for Mood and Anxiety Treatments (CANMAT) task force recommendations for the management of patients with mood disorders and comorbid attention-deficit/hyperactivity disorder. <i>Annals of Clinical Psychiatry</i> , 2012, 24, 23-37.	0.6	74
72	The Influence of Baseline Severity on Efficacy of Escitalopram and Citalopram in the Treatment of Major Depressive Disorder: An Extended Analysis. <i>Pharmacopsychiatry</i> , 2006, 39, 180-184.	1.7	73

#	ARTICLE	IF	CITATIONS
73	Relationship between cognitive functioning and 6-month clinical and functional outcome in patients with first manic episode bipolar I disorder. <i>Psychological Medicine</i> , 2011, 41, 971-982.	2.7	73
74	Efficacy of Vortioxetine on Cognitive Functioning in Working Patients With Major Depressive Disorder. <i>Journal of Clinical Psychiatry</i> , 2017, 78, 115-121.	1.1	73
75	Early Switching Strategies in Antidepressant Non-Responders: Current Evidence and Future Research Directions. <i>CNS Drugs</i> , 2014, 28, 601-609.	2.7	72
76	Discrepancy between objective and subjective cognition in major depressive disorder. <i>European Neuropsychopharmacology</i> , 2019, 29, 46-56.	0.3	71
77	Efficacy and tolerability of extended release quetiapine fumarate monotherapy as maintenance treatment of major depressive disorder: a randomized, placebo-controlled trial. <i>Depression and Anxiety</i> , 2010, 27, 964-976.	2.0	68
78	Onset, time course and trajectories of improvement with antidepressants. <i>European Neuropsychopharmacology</i> , 2012, 22, S492-S498.	0.3	68
79	Comparative Efficacy of Typical and Atypical Antipsychotics as Add-On Therapy to Mood Stabilizers in the Treatment of Acute Mania. <i>Journal of Clinical Psychiatry</i> , 2001, 62, 975-980.	1.1	67
80	Gender differences in the heritability of seasonal mood change. <i>Psychiatry Research</i> , 1997, 70, 145-154.	1.7	66
81	Light visor treatment for seasonal affective disorder: A multicenter study. <i>Psychiatry Research</i> , 1993, 46, 29-39.	1.7	65
82	Brightening Depression. <i>Science</i> , 2004, 303, 467c-469.	6.0	64
83	Neuroprogression and episode recurrence in bipolar I disorder: A study of gray matter volume changes in first-episode mania and association with clinical outcome. <i>Bipolar Disorders</i> , 2016, 18, 511-519.	1.1	64
84	Electroretinography in patients with winter seasonal affective disorder. <i>Psychiatry Research</i> , 2004, 127, 27-34.	1.7	62
85	The Association of Elevated Body Mass Index with Reduced Brain Volumes in First-Episode Mania. <i>Biological Psychiatry</i> , 2011, 70, 381-387.	0.7	62
86	The Canadian Biomarker Integration Network in Depression (CAN-BIND): Advances in Response Prediction. <i>Current Pharmaceutical Design</i> , 2012, 18, 5976-5989.	0.9	61
87	Symptomatic and Functional Outcomes and Early Prediction of Response to Escitalopram Monotherapy and Sequential Adjunctive Aripiprazole Therapy in Patients With Major Depressive Disorder. <i>Journal of Clinical Psychiatry</i> , 2019, 80, .	1.1	61
88	The comparative effectiveness of electroencephalographic indices in predicting response to escitalopram therapy in depression: A pilot study. <i>Journal of Affective Disorders</i> , 2018, 227, 542-549.	2.0	59
89	Atypical depressive symptoms and clusters in unipolar and bipolar depression. <i>Acta Psychiatrica Scandinavica</i> , 1996, 94, 421-427.	2.2	58
90	A controlled trial of the Litebook light-emitting diode (LED) light therapy device for treatment of Seasonal Affective Disorder (SAD). <i>BMC Psychiatry</i> , 2007, 7, 38.	1.1	58

#	ARTICLE	IF	CITATIONS
91	Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 Clinical Guidelines for the Management of Adults with Major Depressive Disorder. <i>Canadian Journal of Psychiatry</i> , 2016, 61, 506-509.	0.9	58
92	Phototherapy for Depressive Disorders: A Review. <i>Canadian Journal of Psychiatry</i> , 1989, 34, 140-147.	0.9	56
93	Treatment of Seasonal Affective Disorder: A Review. <i>Canadian Journal of Psychiatry</i> , 1995, 40, 457-466.	0.9	56
94	A new clinical rating scale for work absence and productivity: validation in patients with major depressive disorder. <i>BMC Psychiatry</i> , 2009, 9, 78.	1.1	56
95	Lurasidone versus treatment as usual for cognitive impairment in euthymic patients with bipolar I disorder: a randomised, open-label, pilot study. <i>Lancet Psychiatry</i> , 2017, 4, 208-217.	3.7	56
96	The Efficacy of Psychostimulants in Major Depressive Episodes. <i>Journal of Clinical Psychopharmacology</i> , 2017, 37, 412-418.	0.7	56
97	Functional outcomes in first-episode patients with bipolar disorder: a prospective study from the Systematic Treatment Optimization Program for Early Mania project. <i>Comprehensive Psychiatry</i> , 2009, 50, 1-8.	1.5	55
98	The Canadian Network for Mood and Anxiety Treatments (CANMAT) Task Force Recommendations for the Use of Racemic Ketamine in Adults with Major Depressive Disorder: Recommendations Du Groupe De Travail Du Réseau Canadien Pour Les Traitements De L'humeur Et De L'anxiété (Canmat) Concernant L'utilisation De La Ketamine Racémique Chez Les Adultes Souffrant De Trouble Dépressif Majeur. <i>Canadian Journal of Psychiatry</i> , 2021, 66, 113-125.	0.9	54
99	A magnetic resonance imaging study of mood stabilizer- and neuroleptic-naïve first-episode mania. <i>Bipolar Disorders</i> , 2007, 9, 693-697.	1.1	53
100	Electroretinography in seasonal affective disorder. <i>Psychiatry Research</i> , 1992, 43, 55-63.	1.7	50
101	Mood disorder service genetic database: Morbidity risks for mood disorders in 3,942 first-degree relatives of 671 index cases with single depression, recurrent depression, bipolar I, or bipolar II. <i>American Journal of Medical Genetics Part A</i> , 1994, 54, 132-140.	2.4	50
102	Which Depressive Symptoms and Medication Side Effects Are Perceived by Patients as Interfering Most with Occupational Functioning?. <i>Depression Research and Treatment</i> , 2012, 2012, 1-6.	0.7	50
103	Adjunctive ketamine in electroconvulsive therapy: Updated systematic review and meta-analysis. <i>British Journal of Psychiatry</i> , 2017, 210, 403-407.	1.7	50
104	Psychometric validation of the Perceived Deficits Questionnaire-Depression (PDQ-D) instrument in US and UK respondents with major depressive disorder. <i>Neuropsychiatric Disease and Treatment</i> , 2018, Volume 14, 2861-2877.	1.0	50
105	Recovery and Recurrence Following a First Episode of Mania. <i>Journal of Clinical Psychiatry</i> , 2015, 76, 1241-1248.	1.1	50
106	Immune-inflammatory markers in patients with seasonal affective disorder: effects of light therapy. <i>Journal of Affective Disorders</i> , 2001, 63, 27-34.	2.0	49
107	12-month longitudinal cognitive functioning in patients recently diagnosed with bipolar disorder. <i>Bipolar Disorders</i> , 2014, 16, 159-171.	1.1	49
108	Use of Machine Learning for Predicting Escitalopram Treatment Outcome From Electroencephalography Recordings in Adult Patients With Depression. <i>JAMA Network Open</i> , 2020, 3, e1918377.	2.8	49

#	ARTICLE	IF	CITATIONS
109	Body Mass Index-Related Regional Gray and White Matter Volume Reductions in First-Episode Mania Patients. <i>Biological Psychiatry</i> , 2014, 76, 138-145.	0.7	48
110	S-adenosyl methionine (SAME) for depression in adults. The Cochrane Library, 2016, 2016, CD011286.	1.5	48
111	Using Metaanalysis to Evaluate Evidence: Practical Tips and Traps. <i>Canadian Journal of Psychiatry</i> , 2005, 50, 167-174.	0.9	47
112	Effects of combined pharmacotherapy and psychotherapy for improving work functioning in major depressive disorder. <i>British Journal of Psychiatry</i> , 2013, 203, 358-365.	1.7	47
113	Growth hormone response to sumatriptan (5-HT _{1D} agonist) challenge in seasonal affective disorder: Effects of light therapy. <i>Biological Psychiatry</i> , 1997, 42, 24-29.	0.7	46
114	Atypical depressive symptoms in seasonal and non-seasonal mood disorders. <i>Journal of Affective Disorders</i> , 1997, 44, 39-44.	2.0	46
115	Accelerated age-related decrease in brain-derived neurotrophic factor levels in bipolar disorder. <i>International Journal of Neuropsychopharmacology</i> , 2009, 12, 137.	1.0	46
116	Efficacy of second generation antipsychotics in treating acute mixed episodes in bipolar disorder: A meta-analysis of placebo-controlled trials. <i>Journal of Affective Disorders</i> , 2013, 150, 408-414.	2.0	46
117	Long-Term and Preventative Treatment for Seasonal Affective Disorder. <i>CNS Drugs</i> , 2007, 21, 901-909.	2.7	45
118	Cognitive Change in the Year After a First Manic Episode. <i>Journal of Clinical Psychiatry</i> , 2014, 75, e587-e593.	1.1	45
119	Morning light therapy for winter depression: predictors of response. <i>Acta Psychiatrica Scandinavica</i> , 1994, 89, 97-101.	2.2	44
120	Mania, Depression, and Mood Dependent Memory. <i>Cognition and Emotion</i> , 1997, 11, 607-618.	1.2	44
121	Our Digital Moment: Innovations and Opportunities in Digital Mental Health Care. <i>Canadian Journal of Psychiatry</i> , 2021, 66, 5-8.	0.9	43
122	Effects of rapid tryptophan depletion in patients with seasonal affective disorder in natural summer remission. <i>Psychological Medicine</i> , 2000, 30, 79-87.	2.7	42
123	Optimal duration of risperidone or olanzapine adjunctive therapy to mood stabilizer following remission of a manic episode: A CANMAT randomized double-blind trial. <i>Molecular Psychiatry</i> , 2016, 21, 1050-1056.	4.1	42
124	The validity of atypical depression in DSM-IV. <i>Comprehensive Psychiatry</i> , 1996, 37, 375-383.	1.5	41
125	Cognitive Dysfunction in Major Depressive Disorder: Assessment, Impact, and Management. <i>Focus (American Psychiatric Publishing)</i> , 2016, 14, 194-206.	0.4	41
126	Antidepressant Drug Studies in the Elderly. <i>Psychiatric Clinics of North America</i> , 1988, 11, 215-233.	0.7	40

#	ARTICLE	IF	CITATIONS
127	Effects of Light Therapy on Suicidal Ideation in Patients With Winter Depression. <i>Journal of Clinical Psychiatry</i> , 2000, 61, 30-32.	1.1	40
128	Seasonal mood symptoms in bulimia nervosa and seasonal affective disorder. <i>Comprehensive Psychiatry</i> , 1991, 32, 552-558.	1.5	39
129	The effects of ultraviolet-A wavelengths in light therapy for seasonal depression. <i>Journal of Affective Disorders</i> , 1992, 24, 237-243.	2.0	39
130	Therapeutic Mechanism in Seasonal Affective Disorder: Do Fluoxetine and Light Operate Through Advancing Circadian Phase?. <i>Chronobiology International</i> , 2005, 22, 937-943.	0.9	39
131	Sleep architecture variation: a mediator of metabolic disturbance in individuals with major depressive disorder. <i>Sleep Medicine</i> , 2013, 14, 943-949.	0.8	39
132	Cognitive impairment as measured by the THINC-integrated tool (THINC-it): Association with psychosocial function in major depressive disorder. <i>Journal of Affective Disorders</i> , 2017, 222, 14-20.	2.0	39
133	Seasonality of symptoms in women with late luteal phase dysphoric disorder. <i>American Journal of Psychiatry</i> , 1997, 154, 1436-1441.	4.0	38
134	Machine learning in the prediction of depression treatment outcomes: a systematic review and meta-analysis. <i>Psychological Medicine</i> , 2021, 51, 2742-2751.	2.7	38
135	The serotonin transporter promoter repeat length polymorphism, seasonal affective disorder and seasonality. <i>Psychological Medicine</i> , 2003, 33, 785-792.	2.7	37
136	Association of peripheral inflammation with body mass index and depressive relapse in bipolar disorder. <i>Psychoneuroendocrinology</i> , 2016, 65, 76-83.	1.3	37
137	Quality of life in bipolar disorder: towards a dynamic understanding. <i>Psychological Medicine</i> , 2018, 48, 1111-1118.	2.7	37
138	Hippocampal tail volume as a predictive biomarker of antidepressant treatment outcomes in patients with major depressive disorder: a CAN-BIND report. <i>Neuropsychopharmacology</i> , 2020, 45, 283-291.	2.8	37
139	The Canadian Biomarker Integration Network in Depression (CAN-BIND): magnetic resonance imaging protocols. <i>Journal of Psychiatry and Neuroscience</i> , 2019, 44, 223-236.	1.4	37
140	Canadian Network for Mood and Anxiety Treatments (CANMAT) consensus recommendations for functional outcomes in major depressive disorder. <i>Annals of Clinical Psychiatry</i> , 2015, 27, 142-9.	0.6	37
141	Systematic review of neurocognition and occupational functioning in major depressive disorder. <i>Neuropsychiatry</i> , 2013, 3, 97-105.	0.4	36
142	L-Tryptophan Augmentation of Light Therapy in Patients with Seasonal Affective Disorder. <i>Canadian Journal of Psychiatry</i> , 1997, 42, 303-306.	0.9	35
143	Effects of Alpha-Methyl-Para-Tyrosine-Induced Catecholamine Depletion in Patients with Seasonal Affective Disorder in Summer Remission. <i>Neuropsychopharmacology</i> , 2001, 25, S97-S101.	2.8	35
144	Eating attitudes in seasonal affective disorder and bulimia nervosa. <i>Journal of Affective Disorders</i> , 1993, 29, 219-225.	2.0	33

#	ARTICLE	IF	CITATIONS
145	Major depression, minor depression, and double depression: Are they distinct clinical entities?. American Journal of Medical Genetics Part A, 1996, 67, 347-353.	2.4	33
146	Seasonality of symptoms in anorexia and bulimia nervosa. , 1996, 19, 35-44.		33
147	Breaking the Myths: New Treatment Approaches for Chronic Depression. Canadian Journal of Psychiatry, 2002, 47, 635-643.	0.9	33
148	Integrated genome-wide methylation and expression analyses reveal functional predictors of response to antidepressants. Translational Psychiatry, 2019, 9, 254.	2.4	33
149	Functional disconnectivity of the hippocampal network and neural correlates of memory impairment in treatment-resistant depression. Journal of Affective Disorders, 2019, 253, 248-256.	2.0	33
150	Light Therapy for Patients With Bipolar Depression: Systematic Review and Meta-Analysis of Randomized Controlled Trials. Canadian Journal of Psychiatry, 2020, 65, 290-300.	0.9	33
151	The relationship between burnout and depressive symptoms in patients with depressive disorders. Journal of Affective Disorders, 2015, 172, 361-366.	2.0	32
152	Monitoring for antidepressant-associated adverse events in the treatment of patients with major depressive disorder: An international consensus statement. World Journal of Biological Psychiatry, 2018, 19, 330-348.	1.3	32
153	Multisite Comparison of MRI Defacing Software Across Multiple Cohorts. Frontiers in Psychiatry, 2021, 12, 617997.	1.3	32
154	Efficacy of Active vs Sham Intermittent Theta Burst Transcranial Magnetic Stimulation for Patients With Bipolar Depression. JAMA Network Open, 2021, 4, e210963.	2.8	32
155	Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) recommendations for the management of patients with bipolar disorder with mixed presentations. Bipolar Disorders, 2021, 23, 767-788.	1.1	32
156	The relationship between seasonal mood change and personality: more apparent than real?. Acta Psychiatrica Scandinavica, 1997, 95, 539-543.	2.2	31
157	The association of weight gain with mood symptoms and functional outcomes following a first manic episode: prospective 12-month data from the Systematic Treatment Optimization Program for Early Mania (STOP-EM). Bipolar Disorders, 2010, 12, 616-626.	1.1	31
158	The impact of childhood trauma on cognitive functioning in patients recently recovered from a first manic episode: Data from the Systematic Treatment Optimization Program for Early Mania (STOP-EM).. Journal of Affective Disorders, 2013, 148, 424-430.	2.0	31
159	Prolactin response to buspirone challenge in the presence of dopaminergic blockade. Biological Psychiatry, 1995, 38, 235-239.	0.7	29
160	A positron emission tomography study of the effects of treatment with valproate on brain 5-HT2A receptors in acute mania. Bipolar Disorders, 2005, 7, 53-57.	1.1	29
161	Weight gain, obesity, and metabolic indices following a first manic episode: Prospective 12-month data from the Systematic Treatment Optimization Program for Early Mania (STOP-EM). Journal of Affective Disorders, 2010, 124, 108-117.	2.0	29
162	A Season-of-Birth/DRD4 Interaction Predicts Maximal Body Mass Index in Women with Bulimia Nervosa. Neuropsychopharmacology, 2010, 35, 1729-1733.	2.8	29

#	ARTICLE	IF	CITATIONS
163	Oxcarbazepine in the Treatment of Bipolar Disorder: A Review. Canadian Journal of Psychiatry, 2006, 51, 540-545.	0.9	28
164	High-quality remission: potential benefits of the melatonergic approach for patients with major depressive disorder. International Clinical Psychopharmacology, 2007, 22, S21-S25.	0.9	28
165	Comparative efficacy of escitalopram in the treatment of major depressive disorder. Neuropsychiatric Disease and Treatment, 2011, 7, 39.	1.0	28
166	Standardization of electroencephalography for multi-site, multi-platform and multi-investigator studies: insights from the canadian biomarker integration network in depression. Scientific Reports, 2017, 7, 7473.	1.6	28
167	Structural network integrity of the central executive network is associated with the therapeutic effect of rTMS in treatment resistant depression. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2019, 92, 217-225.	2.5	28
168	Preferred Features of E-Mental Health Programs for Prevention of Major Depression in Male Workers: Results From a Canadian National Survey. Journal of Medical Internet Research, 2016, 18, e132.	2.1	28
169	Citalopram and bupropion-SR: combining versus switching in patients with treatment-resistant depression. Journal of Clinical Psychiatry, 2004, 65, 337-40.	1.1	28
170	ECT in the Treatment of Mixed Depression and Dementia. British Journal of Psychiatry, 1988, 152, 281-284.	1.7	27
171	Cortisol, Hypothermic, and Behavioral Responses to Ipsapirone in Patients with Bipolar Depression and Normal Controls. Neuropsychobiology, 1998, 38, 6-12.	0.9	27
172	Recent developments in the psychobiology and pharmacotherapy of depression: optimising existing treatments and novel approaches for the future. Expert Opinion on Investigational Drugs, 2003, 12, 65-86.	1.9	27
173	A pilot study of adherence with light treatment for seasonal affective disorder. Psychiatry Research, 2007, 149, 315-320.	1.7	27
174	Do symptoms of bipolar disorder exhibit seasonal variation? A multisite prospective investigation. Bipolar Disorders, 2011, 13, 687-695.	1.1	27
175	Stability, reliability, and validity of the THINC-it screening tool for cognitive impairment in depression: A psychometric exploration in healthy volunteers. International Journal of Methods in Psychiatric Research, 2018, 27, e1736.	1.1	27
176	Implementing Measurement-Based Care for Depression: Practical Solutions for Psychiatrists and Primary Care Physicians. Neuropsychiatric Disease and Treatment, 2021, Volume 17, 79-90.	1.0	27
177	A randomized sham controlled comparison of once vs twice-daily intermittent theta burst stimulation in depression: A Canadian rTMS treatment and biomarker network in depression (CARTBIND) study. Brain Stimulation, 2021, 14, 1447-1455.	0.7	27
178	Generic and health-related quality of life in patients with seasonal and nonseasonal depression. Psychiatry Research, 2004, 128, 245-251.	1.7	26
179	O sweet spot where art thou? Light treatment of Seasonal Affective Disorder and the circadian time of sleep. Journal of Affective Disorders, 2006, 90, 227-231.	2.0	26
180	Escitalopram and duloxetine in the treatment of major depressive disorder: a pooled analysis of two trials. International Clinical Psychopharmacology, 2008, 23, 181-187.	0.9	26

#	ARTICLE	IF	CITATIONS
181	A comparison of open treatment of seasonal major and minor depression with light therapy. <i>Journal of Affective Disorders</i> , 2002, 71, 243-248.	2.0	25
182	The relationship between clinical outcomes and quality of life in first-episode mania: a longitudinal analysis. <i>Bipolar Disorders</i> , 2013, 15, 188-198.	1.1	25
183	Development and implementation of guidelines for the management of depression: a systematic review. <i>Bulletin of the World Health Organization</i> , 2020, 98, 683-697H.	1.5	25
184	An Open Trial of Light Therapy for Women With Seasonal Affective Disorder and Comorbid Bulimia Nervosa. <i>Journal of Clinical Psychiatry</i> , 2001, 62, 164-168.	1.1	25
185	Chronic Schizophrenia and Idiopathic Parkinson's Disease. <i>Canadian Journal of Psychiatry</i> , 1993, 38, 75-77.	0.9	24
186	Long-Term Neuropsychological Safety of Subgenual Cingulate Gyrus Deep Brain Stimulation for Treatment-Resistant Depression. <i>Journal of Neuropsychiatry and Clinical Neurosciences</i> , 2014, 26, 126-133.	0.9	24
187	Enhanced inflammatory and T-helper-1 type responses but suppressed lymphocyte proliferation in patients with seasonal affective disorder and treated by light therapy. <i>Journal of Affective Disorders</i> , 2015, 185, 90-96.	2.0	24
188	Ketamine: stimulating antidepressant treatment?. <i>BJPsych Open</i> , 2016, 2, e5-e9.	0.3	24
189	Testing a deep convolutional neural network for automated hippocampus segmentation in a longitudinal sample of healthy participants. <i>NeuroImage</i> , 2019, 197, 589-597.	2.1	24
190	Is remission of depressive symptoms in primary care a realistic goal? A meta-analysis. <i>BMC Family Practice</i> , 2004, 5, 19.	2.9	23
191	Quality of life as an outcome indicator in patients with seasonal affective disorder: results from the Can-SAD study. <i>Psychological Medicine</i> , 2007, 37, 727.	2.7	23
192	Predictors of functional improvement in employed adults with major depressive disorder treated with desvenlafaxine. <i>International Clinical Psychopharmacology</i> , 2014, 29, 239-251.	0.9	23
193	The effects of desvenlafaxine on neurocognitive and work functioning in employed outpatients with major depressive disorder. <i>Journal of Affective Disorders</i> , 2016, 203, 55-61.	2.0	23
194	Weight gain as a predictor of frontal and temporal lobe volume loss in bipolar disorder: A prospective MRI study. <i>Bipolar Disorders</i> , 2019, 21, 50-60.	1.1	23
195	Clinical, behavioral, and neural measures of reward processing correlate with escitalopram response in depression: a Canadian Biomarker Integration Network in Depression (CAN-BIND-1) Report. <i>Neuropsychopharmacology</i> , 2020, 45, 1390-1397.	2.8	23
196	Evidence-based strategies for achieving and sustaining full remission in depression: focus on metaanalyses. <i>Canadian Journal of Psychiatry</i> , 2004, 49, 17S-26S.	0.9	23
197	Rapid screening for perceived cognitive impairment in major depressive disorder. <i>Annals of Clinical Psychiatry</i> , 2013, 25, 135-40.	0.6	23
198	Hypothermic, ACTH, and cortisol responses to ipsapirone in patients with mania and healthy controls. <i>Journal of Affective Disorders</i> , 1999, 54, 295-301.	2.0	22

#	ARTICLE	IF	CITATIONS
199	Escitalopram versus serotonin noradrenaline reuptake inhibitors as second step treatment for patients with major depressive disorder: a pooled analysis. <i>International Clinical Psychopharmacology</i> , 2010, 25, 199-203.	0.9	22
200	Comparison of neuropsychological effects of adjunctive risperidone or quetiapine in euthymic patients with bipolar I disorder. <i>International Clinical Psychopharmacology</i> , 2012, 27, 91-99.	0.9	22
201	Relationship between frontostriatal morphology and executive function deficits in bipolar I disorder following a first manic episode: data from the Systematic Treatment Optimization Program for Early Mania (STOP-EM). <i>Bipolar Disorders</i> , 2013, 15, 657-668.	1.1	22
202	Early change in reward and punishment sensitivity as a predictor of response to antidepressant treatment for major depressive disorder: a CAN-BIND-1 report. <i>Psychological Medicine</i> , 2019, 49, 1629-1638.	2.7	22
203	Genome-wide analysis suggests the importance of vascular processes and neuroinflammation in late-life antidepressant response. <i>Translational Psychiatry</i> , 2021, 11, 127.	2.4	22
204	Potential therapeutic benefits of cannabinoid products in adult psychiatric disorders: A systematic review and meta-analysis of randomised controlled trials. <i>Journal of Psychiatric Research</i> , 2021, 140, 267-281.	1.5	22
205	Brain serotonin-2 receptors in acute mania. <i>British Journal of Psychiatry</i> , 2010, 196, 47-51.	1.7	21
206	Relief of Chronic or Resistant Depression (Re-ChORD): A pragmatic, randomized, open-treatment trial of an integrative program intervention for chronic depression. <i>Journal of Affective Disorders</i> , 2010, 123, 243-248.	2.0	21
207	White Matter Indices of Medication Response in Major Depression: A Diffusion Tensor Imaging Study. <i>Biological Psychiatry: Cognitive Neuroscience and Neuroimaging</i> , 2019, 4, 913-924.	1.1	21
208	The Efficacy of Measurement-Based Care for Depressive Disorders. <i>Journal of Clinical Psychiatry</i> , 2021, 82, .	1.1	21
209	A Canadian Multicenter Study of Three Fixed Doses of Controlled-Release Ipsapirone in Outpatients With Moderate to Severe Major Depression. <i>Journal of Clinical Psychopharmacology</i> , 1998, 18, 268-273.	0.7	21
210	Bipolar spectrum disorders. New perspectives. <i>Canadian Family Physician</i> , 2002, 48, 896-904.	0.1	21
211	Effects of Divalproex Sodium on 5-HT1A Receptor Function in Healthy Human Males: Hypothermic, Hormonal, and Behavioral Responses to Ipsapirone. <i>Neuropsychopharmacology</i> , 1997, 17, 382-390.	2.8	20
212	Personality and seasonal affective disorder: Results from the CAN-SAD study. <i>Journal of Affective Disorders</i> , 2006, 93, 35-42.	2.0	20
213	Lower cognitive functioning as a predictor of weight gain in bipolar disorder: a 12-month study. <i>Acta Psychiatrica Scandinavica</i> , 2017, 135, 239-249.	2.2	20
214	Trajectories of body mass index change in first episode of mania: 3-year data from the Systematic Treatment Optimization Program for Early Mania (STOP-EM). <i>Journal of Affective Disorders</i> , 2017, 208, 291-297.	2.0	20
215	Reduced accuracy accompanied by reduced neural activity during the performance of an emotional conflict task by unmedicated patients with major depression: A CAN-BIND fMRI study. <i>Journal of Affective Disorders</i> , 2019, 257, 765-773.	2.0	20
216	Light Therapy for Depressive Disorders: Indications and Efficacy. , 1997, 25, 215-234.		19

#	ARTICLE	IF	CITATIONS
217	Growth hormone response to baclofen in patients with mania: a pilot study. <i>Psychopharmacology</i> , 1999, 147, 280-284.	1.5	19
218	Addressing circadian rhythm disturbances in depressed patients. <i>Journal of Psychopharmacology</i> , 2008, 22, 13-18.	2.0	19
219	Positron Emission Tomography Study of the Effects of Tryptophan Depletion on Brain Serotonin ² Receptors in Subjects Recently Remitted From Major Depression. <i>Archives of General Psychiatry</i> , 2012, 69, 601.	13.8	19
220	Antidepressants and QTc prolongation. <i>Journal of Psychiatry and Neuroscience</i> , 2013, 38, E5-E6.	1.4	19
221	Conceptualising the neurobiology of fatigue. <i>Australian and New Zealand Journal of Psychiatry</i> , 2013, 47, 312-316.	1.3	19
222	Effect of Stimulus Intensity on Prolactin and Cortisol Release Induced by Unilateral Electroconvulsive Therapy. <i>Neuropsychopharmacology</i> , 1996, 15, 263-270.	2.8	18
223	Sumatriptan-Induced Growth Hormone Release in Patients with Major Depression, Mania, and Normal Controls. <i>Neuropsychopharmacology</i> , 1997, 17, 258-263.	2.8	18
224	Treatment of seasonal affective disorder: Unipolar versus bipolar differences. <i>Current Psychiatry Reports</i> , 2004, 6, 478-485.	2.1	18
225	Does neuroimmune dysfunction mediate seasonal mood changes in winter depression?. <i>Medical Hypotheses</i> , 2004, 63, 567-573.	0.8	18
226	Escitalopram and QTc prolongation. <i>Journal of Psychiatry and Neuroscience</i> , 2013, 38, E11-E11.	1.4	18
227	Neurocognitive Functioning in Overweight and Obese Patients with Bipolar Disorder: Data from the Systematic Treatment Optimization Program for Early Mania (STOP-EM). <i>Canadian Journal of Psychiatry</i> , 2014, 59, 639-648.	0.9	18
228	Course and outcome following a first episode of mania: Four-year prospective data from the Systematic Treatment Optimization Program (STOP-EM). <i>Journal of Affective Disorders</i> , 2015, 175, 411-417.	2.0	18
229	Revising <i>Diagnostic and Statistical Manual of Mental Disorders</i> , Fifth Edition, criteria for the bipolar disorders: Phase I of the AREDOC project. <i>Australian and New Zealand Journal of Psychiatry</i> , 2018, 52, 1173-1182.	1.3	18
230	A Longitudinal Study of the Relationships Between Mood Symptoms, Body Mass Index, and Serum Adipokines in Bipolar Disorder. <i>Journal of Clinical Psychiatry</i> , 2017, 78, 441-448.	1.1	18
231	Oxcarbazepine add-on in the treatment of refractory bipolar disorder. <i>Bipolar Disorders</i> , 2005, 7, 37-42.	1.1	17
232	Review: The importance of early symptom relief in antidepressant treatment: focus on agomelatine. <i>Journal of Psychopharmacology</i> , 2010, 24, 27-30.	2.0	17
233	Childhood maltreatment and corpus callosum volume in recently diagnosed patients with bipolar I disorder: Data from the Systematic Treatment Optimization Program for Early Mania (STOP-EM). <i>Journal of Psychiatric Research</i> , 2014, 48, 65-72.	1.5	17
234	Implications of Cannabis Legalization on Youth and Young Adults. <i>Canadian Journal of Psychiatry</i> , 2018, 63, 65-71.	0.9	17

#	ARTICLE	IF	CITATIONS
235	Non-linear Entropy Analysis in EEG to Predict Treatment Response to Repetitive Transcranial Magnetic Stimulation in Depression. <i>Frontiers in Pharmacology</i> , 2018, 9, 1188.	1.6	17
236	Childhood maltreatment and cognitive functioning in patients with major depressive disorder: a CAN-BIND-1 report. <i>Psychological Medicine</i> , 2020, 50, 2536-2547.	2.7	17
237	Effects of lamotrigine on the 5-HT1A receptor function in healthy human males. <i>Journal of Affective Disorders</i> , 1998, 49, 157-162.	2.0	16
238	Seasonal mood change and personality: an investigation of genetic co-morbidity. <i>Psychiatry Research</i> , 1998, 78, 1-7.	1.7	16
239	Clinical Predictors of Short-Term Outcome in Electroconvulsive Therapy. <i>Canadian Journal of Psychiatry</i> , 1999, 44, 158-163.	0.9	16
240	Quality of Life in Patients with Seasonal Affective Disorder: Summer vs Winter Scores. <i>Canadian Journal of Psychiatry</i> , 2005, 50, 292-295.	0.9	16
241	Relationship between body mass index and hippocampal glutamate/glutamine in bipolar disorder. <i>British Journal of Psychiatry</i> , 2016, 208, 146-152.	1.7	16
242	It's more than just a referral: Development of an evidence-informed exercise and depression toolkit. <i>Mental Health and Physical Activity</i> , 2019, 17, 100297.	0.9	16
243	Metabolomic signatures associated with depression and predictors of antidepressant response in humans: A CAN-BIND-1 report. <i>Communications Biology</i> , 2021, 4, 903.	2.0	16
244	Does the Addition of Pindolol Accelerate the Response to Electroconvulsive Therapy in Patients with Major Depression? A Double-Blind, Placebo-Controlled Pilot Study. <i>Journal of Clinical Psychopharmacology</i> , 2000, 20, 373-378.	0.7	16
245	Predicting Worsening Suicidal Ideation With Clinical Features and Peripheral Expression of Messenger RNA and MicroRNA During Antidepressant Treatment. <i>Journal of Clinical Psychiatry</i> , 2019, 80, .	1.1	16
246	Effects of chronic lithium treatment on retinal electrophysiologic function. <i>Biological Psychiatry</i> , 1997, 41, 737-742.	0.7	15
247	Abnormal Functional Connectivity of Frontopolar Subregions in Treatment-Nonresponsive Major Depressive Disorder. <i>Biological Psychiatry: Cognitive Neuroscience and Neuroimaging</i> , 2018, 3, 337-347.	1.1	15
248	Predictors of cognitive impairment in treatment-resistant depression. <i>Journal of Affective Disorders</i> , 2020, 274, 593-601.	2.0	15
249	Comparison of fluoxetine and desipramine in depressed outpatients. <i>Current Therapeutic Research</i> , 1993, 53, 457-465.	0.5	14
250	A PET study of brain 5-HT ₂ receptors and their correlation with platelet 5-HT ₂ receptors in healthy humans. <i>Psychopharmacology</i> , 2000, 151, 424-427.	1.5	14
251	Fatigue and occupational functioning in major depressive disorder. <i>Australian and New Zealand Journal of Psychiatry</i> , 2013, 47, 989-991.	1.3	14
252	Selection of cognitive tests for trials of therapeutic agents. <i>Lancet Psychiatry</i> , the, 2016, 3, 499.	3.7	13

#	ARTICLE	IF	CITATIONS
253	Diagnosis and body mass index effects on hippocampal volumes and neurochemistry in bipolar disorder. <i>Translational Psychiatry</i> , 2017, 7, e1071-e1071.	2.4	13
254	Accelerated brain aging in major depressive disorder and antidepressant treatment response: A CAN-BIND report. <i>NeuroImage: Clinical</i> , 2021, 32, 102864.	1.4	13
255	Hypersomnia and morning light therapy for winter depression. <i>Biological Psychiatry</i> , 1992, 31, 1062-1064.	0.7	12
256	Improvements in quality of life with desvenlafaxine 50mg/d vs placebo in employed adults with major depressive disorder. <i>Journal of Affective Disorders</i> , 2014, 166, 307-314.	2.0	12
257	Verbal memory impairment in new onset bipolar disorder: Relationship with frontal and medial temporal morphology. <i>World Journal of Biological Psychiatry</i> , 2015, 16, 249-260.	1.3	12
258	Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 Clinical Guidelines for the Management of Adults with Major Depressive Disorder: Section 5. Complementary and Alternative Medicine Treatments. <i>Focus (American Psychiatric Publishing)</i> , 2018, 16, 85-94.	0.4	12
259	The association of duration and severity of disease with executive function: Differences between drug-naïve patients with bipolar and unipolar depression. <i>Journal of Affective Disorders</i> , 2018, 238, 412-417.	2.0	12
260	Men's Work-Related Stress and Mental Health: Illustrating the Workings of Masculine Role Norms. <i>American Journal of Men's Health</i> , 2019, 13, 155798831983841.	0.7	12
261	Association Between Side Effects and Blood microRNA Expression Levels and Their Targeted Pathways in Patients With Major Depressive Disorder Treated by a Selective Serotonin Reuptake Inhibitor, Escitalopram: A CAN-BIND-1 Report. <i>International Journal of Neuropsychopharmacology</i> , 2020, 23, 88-95.	1.0	12
262	The Relevance of an Employee Assistance Program to the Treatment of Workplace Depression. <i>Journal of Workplace Behavioral Health</i> , 2006, 21, 67-77.	0.8	11
263	The Effects of Newer Antidepressants on Occupational Impairment in Major Depressive Disorder: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. <i>CNS Drugs</i> , 2016, 30, 405-417.	2.7	11
264	Evidence for the Efficacy of Bright Light Therapy for Bipolar Depression. <i>American Journal of Psychiatry</i> , 2018, 175, 905-906.	4.0	11
265	Structural covariance pattern abnormalities of insula in major depressive disorder: A CAN-BIND study report. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2021, 111, 110194.	2.5	11
266	A Randomized Sham-controlled Trial of 1-Hz and 10-Hz Repetitive Transcranial Magnetic Stimulation (rTMS) of the Right Dorsolateral Prefrontal Cortex in Civilian Post-traumatic Stress Disorder: Un essai randomisé contrôlé de stimulation magnétique transcrânienne répétitive (SMTr) de 1 Hz et 10 Hz du cortex préfrontal dorsolatéral droit dans le trouble de stress post-traumatique chez des civils. <i>Canadian Journal of Psychiatry</i> , 2020, 65, 770-778.		11
267	Needs, gaps and opportunities for standard and e-mental health care among at-risk populations in the Asia Pacific in the context of COVID-19: a rapid scoping review. <i>International Journal for Equity in Health</i> , 2021, 20, 161.	1.5	11
268	Light therapy for seasonal bulimia. <i>American Journal of Psychiatry</i> , 1989, 146, 1640-1641.	4.0	11
269	The Effects of an E-Mental Health Program and Job Coaching on the Risk of Major Depression and Productivity in Canadian Male Workers: Protocol for a Randomized Controlled Trial. <i>JMIR Research Protocols</i> , 2016, 5, e218.	0.5	11
270	The Depression Inventory Development Workgroup: A Collaborative, Empirically Driven Initiative to Develop a New Assessment Tool for Major Depressive Disorder. <i>Innovations in Clinical Neuroscience</i> , 2016, 13, 20-31.	0.1	11

#	ARTICLE	IF	CITATIONS
271	Seasonal Affective Disorder: The Latitude Hypothesis Revisited. Canadian Journal of Psychiatry, 2002, 47, 787-788.	0.9	10
272	Core Discrete Event Simulation Model for the Evaluation of Health Care Technologies in Major Depressive Disorder. Value in Health, 2014, 17, 183-195.	0.1	10
273	Research-Track Programs for Residents in Psychiatry: A Review of Literature and a Report of 3 Canadian Experiences. Canadian Journal of Psychiatry, 2014, 59, 268-275.	0.9	10
274	A Positron Emission Tomography Study of Norepinephrine Transporter Occupancy and Its Correlation with Symptom Response in Depressed Patients Treated with Quetiapine XR. International Journal of Neuropsychopharmacology, 2018, 21, 108-113.	1.0	10
275	Structural brain changes in first episode mania with and without psychosis: Data from the Systematic Treatment Optimization Program for Early Mania (STOP-EM). World Journal of Biological Psychiatry, 2018, 19, S30-S40.	1.3	10
276	An investigation of cortical thickness and antidepressant response in major depressive disorder: A CAN-BIND study report. NeuroImage: Clinical, 2020, 25, 102178.	1.4	10
277	Adverse Effects of Pindolol Augmentation in Patients With Bipolar Depression. Journal of Clinical Psychopharmacology, 1999, 19, 383-384.	0.7	10
278	Divalproex Sodium Attenuates Growth Hormone Response to Baclofen in Healthy Human Males. Neuropsychopharmacology, 1998, 18, 370-376.	2.8	9
279	A Community-Based Clinic Survey of Antidepressant Use in Persons with Schizophrenia. Canadian Journal of Psychiatry, 1998, 43, 513-516.	0.9	9
280	Heparin-Based Polyelectrolyte Complex Enhances the Therapeutic Efficacy of Bone Morphogenetic Protein-2 for Posterolateral Fusion in a Large Animal Model. Spine, 2016, 41, 1199-1207.	1.0	9
281	Subcortical structural volumes in recently remitted first episode mania. Journal of Affective Disorders, 2017, 222, 23-27.	2.0	9
282	A multicomponent intervention for the management of chronic pain in older adults: study protocol for a randomized controlled trial. Trials, 2017, 18, 528.	0.7	9
283	Probing the clinical and brain structural boundaries of bipolar and major depressive disorder. Translational Psychiatry, 2021, 11, 48.	2.4	9
284	Symptom Dimension of Interest-Activity Indicates Need for Aripiprazole Augmentation of Escitalopram in Major Depressive Disorder. Journal of Clinical Psychiatry, 2020, 81, .	1.1	9
285	Assessment Scales in Depression and Anxiety - CORPORATE. , 0, , .		9
286	Priorities in treating depression only. International Journal of Psychiatry in Clinical Practice, 2004, 8, 25-29.	1.2	8
287	Direct Health Care Costs of Treating Seasonal Affective Disorder: A Comparison of Light Therapy and Fluoxetine. Depression Research and Treatment, 2012, 2012, 1-5.	0.7	8
288	Risperidone adjunctive therapy duration in the maintenance treatment of bipolar I disorder: A post hoc analysis. Journal of Affective Disorders, 2019, 246, 861-866.	2.0	8

#	ARTICLE	IF	CITATIONS
289	Lithium vs valproate in the maintenance treatment of bipolar I disorder: A post-hoc analysis of a randomized double-blind placebo-controlled trial. Australian and New Zealand Journal of Psychiatry, 2020, 54, 298-307.	1.3	8
290	Exploring brain connectivity changes in major depressive disorder using <sc>functionalâ€structural</sc> data fusion: A CAN-BIND-1 study. Human Brain Mapping, 2021, 42, 4940-4957.	1.9	8
291	Hypothalamus volume and DNA methylation of stress axis genes in major depressive disorder: A CAN-BIND study report. Psychoneuroendocrinology, 2021, 132, 105348.	1.3	8
292	Quality of life impairment in bipolar disorder. , 2007, , 253-274.		8
293	Blue-Light Therapy for Seasonal and Non-Seasonal Depression: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Canadian Journal of Psychiatry, 2022, 67, 745-754.	0.9	8
294	Predicting escitalopram treatment response from pre-treatment and early response resting state fMRI in a multi-site sample: A CAN-BIND-1 report. NeuroImage: Clinical, 2022, 35, 103120.	1.4	8
295	The Lateralization of Atypical Facial Pain. Canadian Journal of Psychiatry, 1988, 33, 100-102.	0.9	7
296	A double-blind, placebo-controlled study of adjunctive calcitonin nasal spray in acute refractory mania. Bipolar Disorders, 2013, 15, 359-364.	1.1	7
297	Sinus Tachycardia Induced by Methocarbamol and Repetitive Transcranial Magnetic Stimulation (rTMS). Brain Stimulation, 2016, 9, 156-158.	0.7	7
298	The impact of fatigue and energy on work functioning and impairment in patients with major depressive disorder treated with desvenlafaxine. International Clinical Psychopharmacology, 2017, 32, 343-349.	0.9	7
299	Efficacy and tolerability of lisdexamfetamine as an antidepressant augmentation strategy: A meta-analysis of randomized controlled trials. Journal of Affective Disorders, 2018, 226, 294-300.	2.0	7
300	Reliability of a functional magnetic resonance imaging task of emotional conflict in healthy participants. Human Brain Mapping, 2020, 41, 1400-1415.	1.9	7
301	Are There Therapeutic Benefits of Cannabinoid Products in Adult Mental Illness?. Canadian Journal of Psychiatry, 2021, 66, 185-194.	0.9	7
302	Association between discrepancy in objective and subjective cognitive abilities and treatment response in patients with major depressive disorder: A CAN-BIND-1 study report. Journal of Affective Disorders, 2021, 295, 1095-1101.	2.0	7
303	The Effects of Ketamine on Cognition in Unipolar and Bipolar Depression. Journal of Clinical Psychiatry, 2022, 83, .	1.1	7
304	Telephone-administered cognitive-behavioral therapy for clients with depressive symptoms in an employee assistance program: a pilot study. Annals of Clinical Psychiatry, 2011, 23, 11-6.	0.6	7
305	ECT-induced prolactin release: Effect of sex, electrode placement and serotonin uptake inhibition. Human Psychopharmacology, 1991, 6, 155-160.	0.7	6
306	Obtaining a Family Psychiatric History: Is it Worth the Effort?. Canadian Journal of Psychiatry, 1993, 38, 590-594.	0.9	6

#	ARTICLE	IF	CITATIONS
307	Research Funding of Psychiatric Disorders in Canada: A Snapshot, 1990–1991. <i>Canadian Journal of Psychiatry</i> , 1994, 39, 141-146.	0.9	6
308	Hard Times and Good Friends: Negative Life Events and Social Support in Patients with Seasonal and Nonseasonal Depression. <i>Canadian Journal of Psychiatry</i> , 2004, 49, 408-411.	0.9	6
309	Preclinical evaluation of strontium-containing bioactive bone cement. <i>Materials Science and Engineering C</i> , 2013, 33, 5100-5104.	3.8	6
310	Midodrine for severe orthostatic hypotension. <i>Drug and Therapeutics Bulletin</i> , 2016, 54, 54-56.	0.3	6
311	A sparse representation-based method for parcellation of the resting brain and its application to treatment-resistant major depressive disorder. <i>Journal of Neuroscience Methods</i> , 2017, 290, 57-68.	1.3	6
312	Escitalopram ameliorates differences in neural activity between healthy comparison and major depressive disorder groups on an fMRI Emotional conflict task: A CAN-BIND-1 study. <i>Journal of Affective Disorders</i> , 2020, 264, 414-424.	2.0	6
313	Baseline Functional Connectivity in Resting State Networks Associated with Depression and Remission Status after 16 Weeks of Pharmacotherapy: A CAN-BIND Report. <i>Cerebral Cortex</i> , 2022, 32, 1223-1243.	1.6	6
314	THE DEPRESSION INVENTORY DEVELOPMENT SCALE: Assessment of Psychometric Properties Using Classical and Modern Measurement Theory in a CAN-BIND Trial. <i>Innovations in Clinical Neuroscience</i> , 2020, 17, 30-40.	0.1	6
315	“One Degree of Separation”: A Mixed-Methods Evaluation of Canadian Mental Health Care User and Provider Experiences With Remote Care During COVID-19. <i>Canadian Journal of Psychiatry</i> , 2022, , 070674372110706.	0.9	6
316	The Clinical Use of EEG in a General Psychiatric Setting. <i>Psychiatric Services</i> , 1988, 39, 533-536.	1.1	5
317	A Psychiatric Fellowship in the United States. <i>Canadian Journal of Psychiatry</i> , 1990, 35, 243-247.	0.9	5
318	Seasonal affective disorders. <i>Current Opinion in Psychiatry</i> , 1994, 7, 9-13.	3.1	5
319	Patients' preferences and counselling for depression in primary care. <i>Lancet, The</i> , 2001, 357, 575-576.	6.3	5
320	Efficacy, effectiveness and efficiency of escitalopram in the treatment of major depressive and anxiety disorders. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2007, 7, 559-576.	0.7	5
321	Quality of Life in Bipolar Disorder: A Review of the Literature. <i>Focus (American Psychiatric)</i> Tj ETQq1 1 0.784314 rgBT/Overlock 10 Tf 50	0.4	5
322	APEC digital hub for mental health. <i>Lancet Psychiatry,the</i> , 2017, 4, e3-e4.	3.7	5
323	Effect of desvenlafaxine 50 mg and 100 mg on energy and lassitude in patients with major depressive disorder: A pooled analysis. <i>Journal of Psychopharmacology</i> , 2017, 31, 1204-1214.	2.0	5
324	Mental Health Service Challenges during the Early Stage of the COVID-19 Pandemic: Experience and Best Practices from China. <i>Canadian Journal of Psychiatry</i> , 2020, 66, 070674372097225.	0.9	5

#	ARTICLE	IF	CITATIONS
325	Serum epidermal growth factor, clinical illness course, and limbic brain volumes in early-stage bipolar disorder. <i>Journal of Affective Disorders</i> , 2020, 270, 30-35.	2.0	5
326	The Quality of Life in Bipolar Disorder (QoLBD) questionnaire a decade on – A systematic review of the measurement of condition-specific aspects of quality of life in bipolar-disorder. <i>Journal of Affective Disorders</i> , 2021, 278, 33-45.	2.0	5
327	Exploring the Effects of Temperament on Gray Matter Volume of Frontal Cortex in Patients with Mood Disorders. <i>Neuropsychiatric Disease and Treatment</i> , 2021, Volume 17, 183-193.	1.0	5
328	Canadian Network for Mood and Anxiety Treatments (CANMAT) Task Force Report: A Systematic Review and Recommendations of Cannabis use in Bipolar Disorder and Major Depressive Disorder. <i>Canadian Journal of Psychiatry</i> , 2023, 68, 299-311.	0.9	5
329	Repeated subcutaneous racemic ketamine in treatment-resistant depression: case series. <i>International Clinical Psychopharmacology</i> , 2022, 37, 206-214.	0.9	5
330	Psychosocial Outcomes following Electroconvulsive Therapy in a Community Setting: Retrospective Chart Review with 2-Year Follow-up. <i>Canadian Journal of Psychiatry</i> , 2007, 52, 598-604.	0.9	4
331	Letter to the Editor. <i>Journal of Neurosurgery</i> , 2012, 116, 467-468.	0.9	4
332	The Prevalence and Impact of Depression in Self-Referred Clients Attending an Employee Assistance Program. <i>Journal of Occupational and Environmental Medicine</i> , 2012, 54, 1395-1399.	0.9	4
333	STAR*D and Measurement-Based Care for Depression: Don't Toss Out the Baby!. <i>Canadian Journal of Psychiatry</i> , 2015, 60, 6-8.	0.9	4
334	Relationship between work functioning and self-reported cognitive complaints in patients with major depressive disorder treated with desvenlafaxine. <i>Psychiatry Research</i> , 2019, 272, 144-148.	1.7	4
335	Reverse translation of major depressive disorder symptoms: A framework for the behavioural phenotyping of putative biomarkers. <i>Journal of Affective Disorders</i> , 2020, 263, 353-366.	2.0	4
336	Cognitive Outcomes with Sequential Escitalopram Monotherapy and Adjunctive Aripiprazole Treatment in Major Depressive Disorder: A Canadian Biomarker Integration Network in Depression (CAN-BIND-1) Report. <i>CNS Drugs</i> , 2021, 35, 291-304.	2.7	4
337	Predictors of Quality of Life Improvement with Escitalopram and Adjunctive Aripiprazole in Patients with Major Depressive Disorder: A CAN-BIND Study Report. <i>CNS Drugs</i> , 2021, 35, 439-450.	2.7	4
338	White matter microstructure in youth at risk for serious mental illness: A comparative analysis. <i>Psychiatry Research - Neuroimaging</i> , 2021, 312, 111289.	0.9	4
339	Replication of machine learning methods to predict treatment outcome with antidepressant medications in patients with major depressive disorder from STAR*D and CAN-BIND-1. <i>PLoS ONE</i> , 2021, 16, e0253023.	1.1	4
340	Barriers and facilitators to implementing measurement-based care for depression in Shanghai, China: a situational analysis. <i>BMC Psychiatry</i> , 2021, 21, 430.	1.1	4
341	<p>The APEC Digital Hub-WONCA Collaborative Framework on Integration of Mental Health into Primary Care in the Asia Pacific</p>. <i>Journal of Multidisciplinary Healthcare</i> , 2020, Volume 13, 1693-1704.	1.1	4
342	Appetitive Symptoms Differentially Predict Treatment Response to Fluoxetine, Light, and Placebo in Nonseasonal Major Depression. <i>Journal of Clinical Psychiatry</i> , 2018, 79, .	1.1	4

#	ARTICLE	IF	CITATIONS
343	Effect of Stimulus Energy on Electroconvulsive Therapy-Induced Prolactin Release. <i>Convulsive Therapy</i> , 1993, 9, 23-27.	0.1	4
344	Do the symptoms of bipolar disorder <i>really</i> show seasonal variation?. <i>Bipolar Disorders</i> , 2013, 15, 808-810.	1.1	3
345	Use of Placebo in Clinical Trials of Psychotropic Medication. <i>Canadian Journal of Psychiatry</i> , 2018, 63, 338-341.	0.9	3
346	Quality of Life Impacts of Bright Light Treatment, Fluoxetine, and the Combination in Patients with Nonseasonal Major Depressive Disorder: A Randomized Clinical Trial. <i>Canadian Journal of Psychiatry</i> , 2021, 66, 289-297.	0.9	3
347	Treatment-emergent and trajectory-based peripheral gene expression markers of antidepressant response. <i>Translational Psychiatry</i> , 2021, 11, 439.	2.4	3
348	Baseline anxiety, and early anxiety/depression improvement in anxious depression predicts treatment outcomes with escitalopram: A CAN-BIND-1 study report. <i>Journal of Affective Disorders</i> , 2022, 300, 50-58.	2.0	3
349	Common Data Elements to Facilitate Sharing and Re-use of Participant-Level Data: Assessment of Psychiatric Comorbidity Across Brain Disorders. <i>Frontiers in Psychiatry</i> , 2022, 13, 816465.	1.3	3
350	Pretreatment anxious depression as a predictor of side effect frequency and severity in escitalopram and aripiprazole adjunctive therapy. <i>Brain and Behavior</i> , 2022, 12, e2555.	1.0	3
351	Seasonal Affective Disorder Presenting as Chronic Fatigue Syndrome. <i>Canadian Journal of Psychiatry</i> , 1991, 36, 680-682.	0.9	2
352	Growth hormone response to baclofen in patients with seasonal affective disorder: effects of light therapy. <i>Psychoneuroendocrinology</i> , 1999, 24, 143-153.	1.3	2
353	Evidence Supports Validity of Seasonal Affective Disorder. <i>Canadian Journal of Psychiatry</i> , 2002, 47, 786-786.	0.9	2
354	Review: antidepressants and psychotherapy may be equally effective for promoting remission in major depressive disorder. <i>Evidence-Based Mental Health</i> , 2003, 6, 45-45.	2.2	2
355	A Comparison of Personality Function Among Patients with Seasonal Depression, Nonseasonal Depression, and Nonclinical Participants. <i>Journal of Personality Disorders</i> , 2004, 18, 448-458.	0.8	2
356	Generalized anxiety disorder: how to treat, and for how long?. <i>International Journal of Psychiatry in Clinical Practice</i> , 2006, 10, 10-15.	1.2	2
357	Challenges in the treatment of anxiety disorders: beyond guidelines. <i>International Journal of Psychiatry in Clinical Practice</i> , 2006, 10, 18-24.	1.2	2
358	Evaluation of a disease management intervention designed to reduce depression disability. <i>Journal of Evaluation in Clinical Practice</i> , 2011, 17, 322-325.	0.9	2
359	Subjective measures of cognitive dysfunction in major depressive disorder. , 2015, , 242-250.		2
360	Advancing Implementation Science Measurement for Global Mental Health Research. <i>Canadian Journal of Psychiatry</i> , 2022, 67, 428-431.	0.9	2

#	ARTICLE	IF	CITATIONS
361	Magnetic Resonance Imaging Sequence Identification Using a Metadata Learning Approach. <i>Frontiers in Neuroinformatics</i> , 2021, 15, 622951.	1.3	2
362	Treatment of depression in patients with dementia. <i>American Journal of Psychiatry</i> , 1990, 147, 130-1.	4.0	2
363	Role of serotonin ₃ receptors in prolactin release induced by electroconvulsive therapy: A study with ondansetron. <i>Psychiatry Research</i> , 1996, 60, 33-39.	1.7	1
364	Advances in treatment of mood and anxiety disorders: focus on atypical antipsychotics. <i>Bipolar Disorders</i> , 2003, 5, 5-6.	1.1	1
365	Acute tryptophan depletion (ATD) induces depressive symptoms in subgroups of recovered depressed patients, including those with seasonal affective disorder (SAD) (Van der Does, 2001a, review).. <i>Psychological Medicine</i> , 2003, 33, 1133-1135.	2.7	1
366	Seasonal Affective Disorders. <i>Issues in Mental Health Nursing</i> , 2012, 33, 266-268.	0.6	1
367	Response to commentaries on the Canadian Network for Mood and Anxiety Treatments/International Society for Bipolar Disorders 2013 updated Bipolar Disorder Guidelines. <i>Bipolar Disorders</i> , 2013, 15, 338-339.	1.1	1
368	Inclusion of mental health in global economic development. <i>BJPsych International</i> , 2018, 15, 74-76.	0.8	1
369	Weight gain as a risk factor for progressive neurochemical abnormalities in first episode mania patients: a longitudinal magnetic resonance spectroscopy study. <i>Psychological Medicine</i> , 2021, , 1-9.	2.7	1
370	Impacts on Quality of Life with Escitalopram Monotherapy and Aripiprazole Augmentation in Patients with Major Depressive Disorder: A CAN-BIND Report. <i>Pharmacopsychiatry</i> , 2021, 54, 225-231.	1.7	1
371	Interactions between neuroticism and stressful life events predict response to pharmacotherapy for major depression: A CAN-BIND 1 report. <i>Personality and Mental Health</i> , 2021, 15, 273-282.	0.6	1
372	Association between the expression of lncRNA BASP-AS1 and volume of right hippocampal tail moderated by episode duration in major depressive disorder: a CAN-BIND 1 report. <i>Translational Psychiatry</i> , 2021, 11, 469.	2.4	1
373	Functional outcomes with bright light in monotherapy and combined with fluoxetine in patients with major depressive disorder: Results from the LIFE-D trial. <i>Journal of Affective Disorders</i> , 2022, 297, 396-400.	2.0	1
374	Cognitive Dysfunction in the Workplace: Focus on Depression. <i>Integrating Psychiatry and Primary Care</i> , 2019, , 99-110.	0.3	1
375	Dr Uher and Colleagues Reply. <i>Journal of Clinical Psychiatry</i> , 2020, 82, .	1.1	1
376	Biophysical compartment models for single-shell diffusion MRI in the human brain: a model fitting comparison. <i>Physics in Medicine and Biology</i> , 2022, 67, 055009.	1.6	1
377	Pain severity and pain interference during major depressive episodes treated with escitalopram and aripiprazole adjunctive therapy: a CAN-BIND-1 report. <i>Psychiatry Research</i> , 2022, 312, 114557.	1.7	1
378	Males and females differ in reported sexual functioning with escitalopram treatment for major depressive disorder: A CAN-BIND-1 study report. <i>Journal of Psychopharmacology</i> , 2022, 36, 604-613.	2.0	1

#	ARTICLE	IF	CITATIONS
379	Review: lithium augmentation increases treatment response in refractory depression. Evidence-Based Mental Health, 2000, 3, 44-44.	2.2	0
380	Editorial. International Journal of Psychiatry in Clinical Practice, 2004, 8, 1-1.	1.2	0
381	Adjunctive Medication Strategies for Treatment- Resistant Depression. Canadian Journal of Psychiatry, 2011, 56, 315-316.	0.9	0
382	From the Guest Editors. Focus (American Psychiatric Publishing), 2016, 14, 155-155.	0.4	0
383	Rating Short-Term Psychodynamic Therapy for the Canadian Network for Mood and Anxiety Treatments Depression Guidelines. Canadian Journal of Psychiatry, 2017, 62, 77-78.	0.9	0
384	Response to Letter Regarding CANMAT Recommendations for the Pharmacological Treatment of Late-life Depression. Canadian Journal of Psychiatry, 2017, 62, 353-354.	0.9	0
385	Comparison of 21 Antidepressants. Focus (American Psychiatric Publishing), 2018, 16, 4s-4s.	0.4	0
386	Neurobiological Aspects of Functional Recovery in Major Depressive Disorder. , 2019, , 277-284.		0
387	Using Machine Learning to Predict Remission in Patients With Major Depressive Disorder Treated With Desvenlafaxine. Canadian Journal of Psychiatry, 2022, 67, 39-47.	0.9	0
388	Author response. Journal of Psychiatry and Neuroscience, 2013, 38, E11-E12.	1.4	0
389	Impact of Cognitive Impairment on Functioning in Patients With Depression. Journal of Clinical Psychiatry, 2017, 78, e1430-e1430.	1.1	0
390	Cognition and Its Association with Psychosocial and Occupational Functioning during Treatment with Escitalopram in Patients with Major Depressive Disorder: A CAN-BIND-1 Report: La Cognition Et Son Association Avec Le Fonctionnement Psychosocial Et Professionnel Durant Le Traitement Par Escitalopram Chez Des Patients Souffrant De Trouble D'Anxiété et de Dépression Majeure: Une Étude Can-Bind-1. Canadian Journal of Psychiatry, 2021, 66, 798-806.	0.9	0
391	Cerebello-cerebral Functional Connectivity Networks in Major Depressive Disorder: a CAN-BIND-1 Study Report. Cerebellum, 2023, 22, 26-36.	1.4	0
392	Response Inhibition and Predicting Response to Pharmacological and Cognitive Behavioral Therapy Treatments for Major Depressive Disorder: A Canadian Biomarker Integration Network for Depression Study. Biological Psychiatry: Cognitive Neuroscience and Neuroimaging, 2023, 8, 162-170.	1.1	0
393	Early optimized pharmacological treatment in patients with depression and chronic pain. CNS Spectrums, 2022, , 1-12.	0.7	0
394	Rhythmicity of sleep and clinical outcomes in major depressive disorder: A CAN-BIND-1 report. Journal of Affective Disorders Reports, 2022, 9, 100370.	0.9	0
395	Acute and chronic stress predict anti-depressant treatment outcome and naturalistic course of major depression: A CAN-BIND report. Journal of Affective Disorders, 2022, 313, 8-14.	2.0	0